Genotyping of Polyomavirus BK by Real Time PCR for VP1 gene by Gambarino, S et al.
The final publication is available at Springer via  
http://link.springer.com/article/10.1007%2Fs12033-011-9386-6
U
N
C
O
R
R
E
C
T
E
D
P
R
O
O
F
RESEARCH1
2 Genotyping of Polyomavirus BK by Real Time PCR for VP1 Gene
3 Stefano Gambarino • Cristina Costa • Sara Astegiano •
4 Elsa Alessio Piasentin • Giuseppe P. Segoloni •
5 Rossana Cavallo • Massimiliano Bergallo
6
7  Springer Science+Business Media, LLC 2011
8 Abstract Polyomavirus BK latently persist in different
9 sites, including the renourinary tract, and may reactivate
10 causing nephropathy in renal transplant recipients or
11 hemorrhagic cystitis in bone marrow recipients. Based on
12 the sequence of the VP1 gene, four genotypes have been
13 described, corresponding to the four serologically differ-
14 entiated subtypes I–IV, with different prevalence and
15 geographic distribution. In this study, the development and
16 clinical validation of four different Real-Time PCR assays
17 for the detection and discrimination of BKV genotypes as a
18 substitute of DNA sequencing are described. 379 BK VP1
19 sequences, belonging to the main four genotypes, were
20 aligned and ‘‘hot spots’’ of mutation specific for all the
21strains or isolates were identified. Specific primers and
22probes for the detection and discrimination of each geno-
23type by four Real-Time PCR assays were designed and
24technically validated. Subsequently, the four Real-Time
25PCR assays were used to test 20 BK-positive urine speci-
26mens from renal transplant patients, and evidenced a
27prevalence of BK genotype I, as previously reported in
28Europe. Results were confirmed by sequencing. The
29availability of a rapid and simple genotyping method could
30be useful for the evaluation of BK genotypes prevalence
31and studies on the impact of the infecting genotype on viral
32biological behavior, pathogenic role, and immune evasion
33strategies.
34
35Keywords Polyomavirus BK  Genotyping  Real-time
36PCR  Sequencing  Prevalence
37Introduction
38BK virus (BKV) belongs to the Polyomaviridae family and
39has a circular double-stranded DNA genome of about
405100 bp [1]. After primary infection that usually occurs in
41the childhood and, which is mainly asymptomatic, BKV
42remains latent at different sites, including the renourinary
43tract, B-cells, and brain [2]. Reactivation with viruria may
44occur, mainly in the context of immunosuppression, and
45potentially lead to nephropathy (BKV-associated nephrop-
46athy—BKVAN) in renal transplant recipients [3] or hem-
47orrhagic cystitis in bone marrow transplant patients [4].
48BKV is the only primate polyomavirus with serologi-
49cally differentiated subtypes (I-IV) [5]. Jin and colleagues
50developed a genotyping method based on the amplification
51of the epitope region of the VP1 gene by polymerase chain
52reaction (PCR) and classified viral isolates in four different
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53 genotypes (BKV I-IV) corresponding to the serological
54 ones [6].
55 The geographical distribution of BKV subtypes has been
56 investigated in different studies [7–10], evidencing a higher
57 prevalence for BKV I worldwide and a minor but consis-
58 tent occurrence of BKV IV, in particular in South-East
59 Asia. On the other hand, the prevalence of BKV II and
60 BKV III is very low with a higher presence of BKV III in
61 the African continent. This genotyping method is based on
62 the presence of single nucleotide polymorphisms (SNPs)
63 conserved between the various isolates belonging to each
64 of the four genotypes. Many different biomolecular pro-
65 cedures have been developed to detect and discriminate
66 SNPs [11–14]; among these, the ARMS PCR [15] uses the
67 discriminatory power of the terminal 30 nucleotide to obtain
68 a successful amplification only for the DNA strand with a
69 correct complementariness.
70 In this article, we describe the design of four different
71 Real-Time PCR assays which can detect and discriminate
72 among the four main BKV genotypes (I–IV) as a valid
73 substitute of DNA sequencing.
74 Materials and Methods
75 BKV Sequences and Phylogenetic Analyses
76 379 BKV VP1 sequences, belonging to the main four
77 genotypes (I–IV), were obtained from three different arti-
78 cles [8–10] by extrapolation from the server Nucleotide
79 (www.ncbi.nlm.nih.gov/nucleotide/). Nucleotide positions
80 from 1663 to 1912 (Dunlop strain complete genome,
81 GeneBank Access no. V01108) were considered to obtain
82 250-bp length DNA sequences. Subsequently, the VP1
83 DNA sequences were aligned using the software Clustal X
84 (i.e., the graphical version, with windows interface, of the
85 bioinformatic software Clustal W). This software, that
86 incorporates a novel position-specific scoring scheme and a
87 weighting scheme for down weighting over-represented
88 sequence groups, is used for multiple sequence alignment
89and phylogenetic analysis, with the possibility to draw
90phylogenetic trees. The software BioEdit was used to
91manipulate the alignment for a clearer sight of differences
92between the aligned sequences. BioEdit software is a user-
93friendly tool for post-alignment modifications, with the
94possibility to emphasize few sequences, cut and paste
95them, and make other evaluations, such as restriction
96mapping. The BKV VP1 sequences were then used for
97Phylogenetic analyses. Clustal X, that was utilized to make
98a neighbor-joining phylogenetic tree, and the free software
99NJplot were employed to display the resulting tree. The
100confidence of branching patterns of the neighbor-joining
101tree was determined by bootstrap analysis, using a set of
1021,000 replicates.
103Primers and Probes Design
104The alignment was screened to find ‘‘hot spots’’ of muta-
105tion specific for all the strains or isolates belonging to each
106genotype (Fig. 1). In the absence of a specific single
107nucleotide mutation, the occurrence of a different nucleo-
108tide combination between the genotypes was considered.
109Every mutation was evaluated as a possible target for
110designing of a set of primers able to recognize all the BKV
111strains belonging to a specific genotype and to discriminate
112between the others by a mismatch at the 30 primer ending.
113The parameters that were taken into consideration for
114selecting the ‘‘hot spots’’ and discriminating the primers
115design were the presence of a unique sequence shared
116between the strains belonging to one genotype but not to
117the others, the 60C melting temperature, and the possi-
118bility to design a Real-Time PCR probe in the most con-
119served nucleotide region inside the hypothetic amplicon.
120Primers and probes were designed with the help of the
121software Primer Express
 v3.0 (Applied Biosystem,
122Cheshire, UK). The primers obtained were then analyzed
123with the Autodimer Software, an open-source tool that
124evaluates the hairpin and primer–dimer formation, with the
125aim of excluding the presence of factors that could alter the
126amplification efficiency. In order to include all the strains
Fig. 1 Regions considered for the primer and probe design. Identical residues are represented as dots. Light squares indicate the primer regions.
Dark squares represent the probe regions
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127belonging to one genotype, many pairs of primers were
128designed and produced. Four Taqman
 probes MGB
129(minor groove binding) labeled at the 50 end with FAM
130(6-carboxyfluorescein), each being able to recognize one of
131the four target regions amplified by the different pairs
132of primers, were also designed. The list and sequences of
133primers and probes are reported in Table 1.
134Real-Time PCR Optimization
135Four different mixes for the amplification of each genotype
136were prepared. Different concentrations of primers and
137probe were evaluated: in particular, 200/200, 200/100,
138100/200, 200/50, and 50/200 nM for primer forward/
139reverse, and 250 or 100 nM for probe. The reaction mix-
140ture contained 19 Master Mix (Platinum qPCR super-
141mix—UDG with ROX [Invitrogen, Carlsbad, CA]). For
142this evaluation, isolates from BKV I (Dunlop strain) and
143BKV IV (kindly provided by Dr. Andi Krumbholz and Dr.
144Ellen Krautkramer), and ultramers that simulated BKV II
145and III sequences (comprehending a portion of isolates
146ETH3 and NEA27, respectively [Tema Ricerca, Bologna,
147Italy]), were used. Fifteen microliters of amplification mix
148were added to 5 ll of BKV DNA, obtaining a final volume
149of 20 ll. The procedure was performed and optimized on
150the 7300 Real-Time PCR System (Applied Biosystems).
151The following thermal profile was used: one cycle of
152decontamination at 50C for 2 min, one cycle of denatur-
153ation at 95C for 10 min, and followed by 45 cycles of
154amplification at: 95C for 15 s, and 60C for 60 s. The
155following parameters were considered for the evaluation:
156quick observation of the amplification, and good discrim-
157ination between the specific and aspecific amplification.
158Plasmids and Standards
159The BKV I Dunlop standard plasmid was kindly provided
160by Prof. Tiziana Musso. The BKV II and BKV III standard
161plasmids were produced starting from the ultramers (Tema
162Ricerca), then amplified with cloning primers (Table 1).
163The BKV IV standard plasmid was prepared starting from
164the BKV IV isolate J/2296/04 (kindly provided by Dr. Andi
165Krumbholz). The primers were used for producing a PCR
166product, then cloned using the pTOPO–TA cloning system
167(Invitrogen) and propagated in competent Escherichia coli
168TOP10 cells. After overnight culture, selected transformed
169clones were amplified by culture in liquid LB medium
170(10 g BACTOTRYPTONE, 5 g yeast extract, 171 mM
171NaCl, and 15 g/l agar, pH 7.5) containing 50 lg/ml of
172ampicillin. Plasmid DNA was extracted and purified using
173the Wizard Plus SV Miniprep DNA Purification System
174(Promega, Madison, WI). The plasmid concentration was
175estimated on spectrophotometric reading at OD260.T
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176 Real-Time PCR Evaluation (Linearity, Efficiency,
177 Interference Limit, Limit of Detection, Precision)
178 The four genotyping assays were evaluated using serial
179 10-fold dilutions of the target plasmid (ranging from 10
7 to
180 10 copies per reaction). The linearity was assessed by the
181 correlation coefficient (R
2) of the standard curve obtained by
182 plotting 10
7–10 standard copies per reaction with the four
183 different tests. The efficiency was evaluated by the slope of
184 the standard curve, using the formula E = 10
(-1/slope)-1.
185 In order to discriminate between specific and aspecific
186 amplifications, three repetitions of 10
7, 105, and 103, and 10
187 copies per reaction of the four standards were amplified with
188 the four different genotyping mixes. The average threshold
189 cycle (Ct) values of specific and aspecific amplifications
190 were obtained. The background Ct was evaluated by the
191 formula Ctlim = Cta-t0.01•ra/N, where N is the number of
192 observations, and t0.01 is the tabulated value of Student’s t for
193 the 1% probability level and N-1 degree of freedom [16].
194 For the evaluation of the lowest genotype concentration that
195 could be distinguished from the aspecific amplification of the
196 other three genotypes, the formula IL ¼ 100=ð2ðCtsCtlimÞ þ
197 1 was used, where Cts represents the specific Ct [17].
198 The limit of detection, defined as the lowest target
199 quantity detectable, was also estimated by serial 10-fold
200 standard dilutions. The precision of each test was calcu-
201 lated by the intra- and inter-test coefficients of variation,
202 according to the formula CV = 100•(r/MC), where MC is
203 the average measured concentration, and r the correspon-
204 dent standard deviation. Three repetitions for each standard
205 dilution were considered in the same run or in different
206 experiments, for the intra- and the inter-assay coefficients
207 of variation, respectively.
208 Clinical Specimens
209 Twenty urine specimens resulting positive to a reference
210 amplification assay (BKV Q-PCR Alert Kit [Nanogen,
211 Buttigliera Alta, Turin, Italy]) were tested with the four
212 amplification assays to assess the genotyping procedure.
213 Automated DNA extraction was performed with the
214 NucliSens EasyMAG platform (bioMerie´ux, Marcy l’Eto-
215 ile, France) from 1 ml of urine, according to the manu-
216 facturer’s instructions, and eluted to a final volume of
217 50 ll. Five microliters of extracted specimen were then
218 added to 15 ll of each genotyping mix. The results were
219 analyzed using the System SDS software.
220 Sequencing Procedure
221 To confirm the results obtained by the Real-Time ampli-
222 fication, sequencing procedure was performed. The 20
223specimens were amplified with primers BKV-1 (50-GAA
224GTT CTA GAA GTT AAA ACT GGG-30) and BKV-2
225(50-GTG GAA ATT ACT GCC TTG AAT AGG-30) [9],
226obtaining an amplicon of 354 nucleotides within the VP1
227gene (from 1663 to 2016, Dunlop reference numbering).
228The amplification mix contained 6 ll of GoTaq
 HotStart
229Polymerase buffer 59 (Promega), 200 lM of each dNTP,
2306 mM of MgCl2, 1 unit of GoTaq
 HotStart Polymerase
231(Promega), and 20 pmol of BKV-1 and BKV-2 primers,
232respectively. The resulting amplicons were run on agarose
233gel (2% w/v) by electrophoresis, the gel was observed on
234an UV transilluminator UV and the bands cut. Subse-
235quently, the bands were purified using the Nucleospin

236Extract II (Macherey–Nagel, Du¨ren, Germany). The puri-
237fied PCR products were sequenced using the BigDye

238Terminator v1.1 Cycle Sequencing Kit (Applied Biosys-
239tem). In brief, a mix containing 8 ll of Terminator Ready
240reaction mix, 2 ll of PCR product, 3.2 pmol of inner pri-
241mer (BKV-1 or BKV-2), and deionized water to obtain
24220 ll final volume was prepared. Then, the Cycle
243sequencing was carried out on 9800 Fast Thermal Cycler
244(Applied Biosystem) with an initial denaturation step at
24596C for 1 min, followed by 25 cycles of 96C for 10 s,
24650C for 5 s, and 60C for 4 min.
247The Cycle sequencing product was then purified by
248Ethanol/EDTA/Sodium Acetate precipitation and loaded
249onto the ABI PRISM 31 Genetic Analyzer (Applied Bio-
250system). Forward and reverse sequences were aligned with
251the ClustalX sotware and then compared to BKV
252sequences.
253Results
254The best amplification was obtained with the following
255concentrations of primers forward/reverse: 100/200,
256200/200, 200/200 and 200/100 nM for genotypes I, II, III,
257and IV, respectively, and with a probe concentration of
258250 nM; however, the amplification efficiencies were 104,
259104, 97, and 88%, respectively. The R
2 coefficient was
2600.996, 0.999, 0.995, and 0.999 for BK I, II, III, and IV
261genotype amplifications, respectively.
262Subsequently, the Real-Time PCRs were tested for the
263discrimination of the four genotypes. Three repetitions of
26410
7, 105, and 103, and 10 copies/reaction of the target
265sequence of themain four BKV genotypes were employed to
266compare the amplification and distinguish between specific
267and aspecific amplifications using the four mixes (Table 2).
268As regards the BKV I genotype mix, this resulting product
269was able to amplify the genotype I-specific target, and only
270BKV II and IV genotype mixes cross-recognize the specific
271genotype I target at 10
7 copies/reaction (both), and at 105
272copies/reaction (only the BKV II genotype mix). However, a
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273 gap of approximately 14.8–14.68 Cts separated the specific
274 and aspecific amplifications; moreover, no aspecific ampli-
275 fication was evidenced for lower dilution.
276 BKV II genotype mix that resulted was able to amplify
277 the specific BKV II target sequence;’ however, this was
278 also amplified by the other three BKV discriminating
279 mixes. Only the amplification of the BKV II-specific target
280 with the corresponding mix was linear, and the threshold
281 crossing appeared at least 15 cycles earlier for BKV II mix
282 at 10
7 copies/reaction compared to the other amplification
283 mixes, decreasing to six cycles at 10
3 copies/reaction. The
284 amplification with BKV II mix at lower BKV II genotype-
285 specific target concentration was considered not discrimi-
286 nating, because of the overlapping Ct with BKV III and IV
287 amplification mixes. The BKV III target was recognized by
288 the corresponding mix with a linear amplification; how-
289 ever, 10
7 copies/reaction were recognized also by the BKV
290 I mix, although a mean gap of 17.84 Cts was observed
291 between specific and aspecific amplifications. An undis-
292 tinguishable specific amplification was seen with a con-
293 centration of BKV III of 10 copies/reaction, because of the
294 simultaneous amplification with BKV II, III, and IV mixes
295 with a similar Ct. The BKV IV target showed a specific
296recognition using the corresponding mix, although the
297target was also amplified with BKV II and III mixes at 10
7
298copies/reaction, with a mean gap of 18.21 and 18.45 Cts
299between specific and aspecific amplifications for BKV II
300and III mixes, respectively. However, at a concentration of
30110
3 copies/reaction, the target was also recognized by BKV
302I mix with a mean gap of 4.48 mean Cts.
303Using the same data to evaluate the specific and aspe-
304cific amplifications, a Ctlim was calculated for each geno-
305typing amplification, as an interference limit (Table 3). The
306precision was calculated with the intra- and inter-test
307coefficients of variation (Table 4).
308In order to establish the limit of detection for the four dif-
309ferent genotyping amplifications, 10-fold dilutions of the
310targets (ranging from 10
7 to 10 copies/reaction) were ampli-
311fied with the above four methods. The limit of detection dif-
312fered between the four genotyping amplification procedures
313and was as follows: 10
2 copies/reaction for BKV IV and 10
314copies/reaction for BKV I, II, and III, each. However, only
315BKV III procedure showed a sensitivity of 10 copies/reaction,
316while for the others assay, it was of 100 copies/reaction.
317Results for the clinical specimens are reported in Table 5.
318In brief, the amplification procedures yielded positive results
Table 2 Aspecific and specific means Ct for each genotyping mix
Specific mean Ct Aspecific mean Ct
BK I BK II BK III BK IV
107 17.36 (0.07) 32.16 (0.34) [32.06]
105 24.12 (0.07) 38.8 (0.16) [38.75] 38.13
103 30.9 (0.51)
10 36.12
BK II BK I BK III BK IV
107 16.85 (0.04) 36.57 (0.62) [36.39] 32.2 (0.36) [32.10]
105 23.21 (0.04) 35.94 (0.65) [35.75]
103 29.97 (0.19) 36.14 37.74 36.51 (0.94) [36.24]
10 36.03 40.89 37.15
BK III BK I BK II BK IV
107 17.78 (0.16) 35.62 (0.9) [35.36]
105 24.2 (0.16)
103 30.84 (0.03)
10 37.62 (0.63) 36.91 38.61 (0.74) [38.40]
BK IV BK I BK II BK III
107 17.67 (0.03) 36.12 (0.81) [35.89] 35.88 (0.59) [35.71]
105 24.74 (0.01)
103 32.3 (0.19) 36.78
10
The values in the round brackets are the standard deviations of the repetitions for each dilution; in the square brackets the Ctlim are reported (see
text for explanation)
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319 in 16 cases; in particular: 12716 BKV I, 1/16 BKV II, 1716
320 BKV III, and 1/16 BKV IV. TheDNA sequencing confirmed
321 the results obtained with the Real-Time PCR assays for all
322 the samples. One specimen (#4464) showed a concomitant
323 amplification for BKV I and BKV IV, with overlapping Cts;
324 sequencing identified it as BKV I genotype.
325 In most of the cases, the viral load found with the devel-
326 oped methods differed from that obtained with the reference
327 method, with a percentage of variation ranging from-288.4
328 to 89.9% (Table 5). Furthermore, more aspecific amplifica-
329 tionswere observed in clinical specimens. In fact, the sample
330 #2998 showed two aspecific plots (BKV I andBKV II), while
331 no BKV I amplification was observed with a 10
7 copies/
332 reaction plasmid dilution. Nevertheless, the occurrence of
333 aspecific amplifications did not impact on the genotyping
334 performance of the Real-Time PCRs, as the gap between the
335 curves of amplifications remained wide.
336 Discussion
337 In this study, a Real-Time PCR-based method for geno-
338 typing of polyomavirus BK was developed. By
339hemagglutination inhibition tests, four main BKV sero-
340types were described [5], based on the differences in a short
341amino acidic sequence on VP1 protein, probably being
342responsible for the serotypical differences among BKV
343variants [18]. Correspondingly, four main BKV VP1
344genotypes were found, and their nucleotide sequences
345analyzed [18]. On the basis of this conserved region, 379
346VP1 sequences were collected from three different articles
347[8–10] investigating the prevalence of BKV subtypes in
348different countries, including Germany, Japan, and China.
349These sequences were aligned to determine which nucle-
350otide residues were conserved within each genotype with
351the aim to design a Real-time PCR assay based on the
352principle of the Amplification Refractory Mutation Assay
353(ARMS).
354A complete list of single nucleotide polymorphisms in
355the total BKV genome for each genotype has been reported
356[19]. The 379 aligned VP1 sequences presented concordant
357residues with those previously listed by Luo and colleagues
358[19], confirming the uniqueness and conservation of these
359polymorphisms among the genotypes.
360It has been reported [19] that genotyping on large T
361antigen (LTA) is preferable, in particular, because LTA is a
362larger region with more informative sites compared to the
363327 bp of VP1 region considered by Jin and colleagues [6].
364However, in this study, we chose to use the VP1 region
365instead of LTA as we aimed to produce powerful dis-
366criminating Real-Time PCRs taking into consideration the
367data published in the literature. Indeed, a higher number of
368sequences is banked in public domain servers for VP1
369compared to LTA, thus permitting a more detailed primers-
370and-probes design for the detection of a higher number of
371sequences and corresponding polymorphic residues. In this
372study, four Real-Time PCR assays, each one that can
373amplify specifically a specific genotype, were designed,
374and four different amplification mixes were produced to
375avoid a too high concentration of primers in a single well,
376that could determine dimer formation or an increase in the
377aspecific performance. In fact, in the presence of high viral
378loads, aspecific amplifications might appear, and these
379were detectable as a low quantity amplification with other
380genotype mixes; anyway, the aspecific amplification was
381easily recognizable by the wide gap between the specific
382and aspecific plots. Moreover, the introduction of Ctlim and
383interference limit gave further clues about discrimination.
384Clearer results were available for 10
7–105 copies/reaction
385dilutions, while 10
3 caused the lowest dilution with an
386acceptable genotyping performance. For this reason, a
387result comparable to 10
3 was set as genotyping limit for all
388the four Real-Time PCRs, and all those results with a lower
389quantity were not accepted.
390As regards the clinical validation of the four genotyping
391assays, the distribution of BKV genotypes was evaluated in
Table 3 Interference limit
107 (%) 105 (%) 103 (%) 10 (%)
I–II 0.00375 0.00393
II–III 0.00013
II–IV 0.00257 0.01674 1.27874
III–IV 0.00051 36.83754
IV–[II 0.00033
IV–III 0.00037
The lowest limit of quantity of BKV-specific genotype, expressed in
percentage, distinguishable from the background (aspecific amplifi-
cation). In the case of no reported percentage, sporadic or no back-
ground amplification was observed
Table 4 Intra- and inter-assay coefficients of variation for dilutions
of 107, 105, and 103, and 10 copies/reaction
107 (%) 105 (%) 103 (%) 10 (%)
Coefficient of intra-assay variation
I 0.40 0.29 1.65
II 0.23 0.17 0.63
III 0.89 0.66 0.10 1.67
IV 0.16 0.04 0.59
Coefficient of inter-assay variation
I 0.92 2.70 0.84 1.85
II 1.19 0.15 1.45 0.99
III 1.30 1.51 0.91 2.92
IV 3.34 2.20 2.26
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392 urine specimens; this type of sample was chosen for the
393 higher mean viral load in comparison to serum samples [2].
394 However, clinical samples with a low reference viral load
395 were not always detected. Most of the specimens were
396 infected by BKV I (80%), while BKV II, III, and IV were
397 infrequent. The prevalence of the four genotypes was
398 concordant with the literature [20]. BKV IV, that is more
399 prevalent in East Asia [8], is found also in Europe [9] in a
400 percentage comparable to the one observed by us; however,
401 notwithstanding the uncommon prevalence, both BKV II
402 and BKV III were detected in two different samples; the
403 results were confirmed by the subsequent VP1 DNA
404 sequencing.
405 Considering viral load of different genotypes, a high
406 divergence was observed between the genotyping assays
407 and the reference method, with a variability ranging from
408 -288.4 to 89.9%. These data highlighted the problem
409 exposed by Hoffman and coll. [21]: in the presence of
410 various genotypes, difference in probes and primers for the
411 BKV quantification led to a substantial disagreement
412 between assays. This was confirmed in our study, between
413 the reference and the genotyping amplifications.
414 In conclusion, the four Real-Time PCRs that were pro-
415 duced were able to detect and discriminate the main four
416 BKV genotypes. Compared to classical DNA sequencing,
417these procedures are more rapid and simpler, since they are
418single PCR assays with no purification steps; results are
419available in approximately 2 h. One drawback could arise
420because of the need of at least 10
3 copies/reaction for the
421genotyping; in these cases, a PCR assay employing exter-
422nal primers, or other protocols, would be necessary to
423increase the target sequence amplifiable, although this
424should also increase the time required for genotyping.
425The comparison between genotyping procedures on
426clinical samples and plasmid dilutions evidenced some
427differences, including the detection of aspecific plots dur-
428ing the testing of clinical samples, and the lack of similarity
429with the quantities reported by the reference amplification
430procedure. This could be caused by the primers-and-probes
431nature, amplifying Large T (reference method) and VP1,
432and by the presence of polymorphism that alter the effi-
433ciency of amplification, as previously suggested [21].
434Nevertheless, the four Real-Time PCRs developed in this
435study should not be considered quantitative methods, as the
436procedures were not tested for the quantification of a broad
437number of isolates. The availability of a rapid and simple
438genotyping test could be useful for the evaluation of BKV
439genotypes’ prevalence. and studies on the impact of the
440infecting genotype on viral biological behavior, pathogenic
441role, and immune evasion strategies.
Table 5 BK genotyping in clinical specimens
N ID Reference copies/ml BKV I (Ct) BKV II (Ct) BKV III (Ct) BKV IV (Ct) Genotype Copies/ml
1 2998 [5 9 106 31.63 33.82 11.59 IV [5 9 107
2 3068 4237203 19.57 36.36 32.78 I [5 9 107
3 3204 569
4 3206 [5 9 106 12.01 26.65 25.34 I [5 9 107
5 3207 2413 30.60 I 5379 (-122.9%)
6 3607 126470 29.38 36.56 I 12800 (89.9%)
7 3619 1542
8 3965 502131 24.72 43.06 38.04 I 351153 (30.1%)
9 4011 868
10 4063 4158 30.14 I 7458 (-79.4%)
11 4326 495 34.78 I \500
12 4398 49606 29.73 43.09 38.53 I 9981 (79.9%)
13 4405 2472943 34.93 19.80 32.37 II 1220410 (50.6%)
14 4464 8689 36.59 36.69 I \500
15 4674 6441 29.22 42.79 42.64 I 14342 (-122.7%)
16 4712 2393 30.58 37.65 I 5456 (-128%)
17 4714 \59 36.17 I \500
18 4723 [5 9 106 12.19 28.37 26.11 I [5 9 107
19 4758 \59
20 4768 44562 31.50 29.14 III 173076 (-288.4%)
Viral loads (expressed in copies/ml) of positives samples for the reference method, positivity to each amplification procedure (expressed in Ct),
genotype and quantities (expressed in copies/ml) are reported. Bold numbers shows Cts of overlapping curves
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